Clinical Trial Update: A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) [Phase 2]

View source ↗

Summary

Phase 2 pilot trial of oral vorinostat plus eltrombopag in lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Promacta (eltrombopag)
• Zolinza (vorinostat)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Status: TERMINATED